Alfacalcidol Capsules

1. Increase the reabsorption of calcium by the small intestine and renal tubules, inhibit parathyroid hyperplasia, reduce the synthesis and release of parathyroid hormone, and inhibit bone resorption; 2. Increase the synthesis of transforming growth factor-beta (TGF-beta) and insulin-like growth factor-I (IGF-I), and promote the synthesis of collagen and bone matrix protein; 3. Regulate muscle calcium metabolism, promote muscle cell differentiation, enhance muscle strength, increase neuromuscular coordination, and reduce the tendency to fall.

The main ingredient of this product is: Alfacalcidol.

This product is a capsule, and the contents are white or off-white powder.

1. Rickets and osteomalacia. 2. Renal osteodystrophy. 3. Osteoporosis. 4. Hypoparathyroidism.

Oral administration: Adults, 0.25-1 μg per day.

Small doses alone (1.0 mu; g/d) generally have no adverse reactions, but long-term high-dose use or combined use with calcium supplements may cause hypercalcemia and hypercalciuria.

It is contraindicated for patients who are allergic to vitamin D and its analogs, have hypercalcemia, or have signs of vitamin D poisoning.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: There is currently no sufficient safety data. Pregnant women, women who may become pregnant, and lactating women should weigh the benefits to the fetus and infant and use it only under the doctor's advice when the risks outweigh the risks. Precautions for the elderly: Not yet clear.

1 Calcium agents: Combination with calcium agents may cause elevated blood calcium, so blood calcium should be monitored. 2 Thiazide diuretics: This type of diuretic can promote the kidney's absorption of calcium, and there is a risk of hypercalcemia when used together. 3 Digitalis glycosides: Hypercalcemia in patients taking digitalis drugs can easily induce arrhythmias. If this drug is used in combination, blood calcium should be closely monitored. 4 Barbiturates, anticonvulsants: These drugs can accelerate the metabolism of active vitamin D metabolites in the liver and reduce the efficacy of the drug, so the dose of this drug should be appropriately increased. 5 Gastrointestinal absorption inhibitors: Cholestyramine or aluminum-containing antacids can reduce the absorption of this drug. The two should not be taken at the same time. The drugs should be taken one after the other with an interval of 2 hours. 6 Phosphorus agents: This product can induce hyperphosphatemia when used in combination with large doses of phosphorus agents.

Sealed and stored in a cool place.

0.5 μg

Tentative 18 months

INNER Mongolian Kangchen Pharmaceutical Industry Co., Ltd.

• Founded in:

  2005-12-29

• Address:

  North of No. 2 Road, Ganqika Industrial Park, Horqin Left Rear Banner, Tongliao City, Inner Mongolia Autonomous Region

• Tax NO.:

  91150522783012103C

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view